Cormorant Asset Management, LP Cabaletta Bio, Inc. Transaction History
Cormorant Asset Management, LP
- $992 Million
- Q2 2025
A detailed history of Cormorant Asset Management, LP transactions in Cabaletta Bio, Inc. stock. As of the latest transaction made, Cormorant Asset Management, LP holds 5,000,000 shares of CABA stock, worth $12.2 Million. This represents 0.77% of its overall portfolio holdings.
Number of Shares
5,000,000Holding current value
$12.2 Million% of portfolio
0.77%Shares
13 transactions
Others Institutions Holding CABA
# of Institutions
94Shares Held
77.1MCall Options Held
406KPut Options Held
90.9K-
Bain Capital Life Sciences Investors, LLC Boston, MA9.68MShares$23.6 Million4.41% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA8.83MShares$21.5 Million0.02% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD6.79MShares$16.6 Million0.01% of portfolio
-
Jennison Associates LLC6.02MShares$14.7 Million0.01% of portfolio
-
Alyeska Investment Group, L.P. Chicago, IL4.8MShares$11.7 Million0.03% of portfolio
About Cabaletta Bio, Inc.
- Ticker CABA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 29,014,000
- Market Cap $70.8M
- Description
- Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce di...